logo
‘Whole again': Man receives double hand transplant after nearly 17 years

‘Whole again': Man receives double hand transplant after nearly 17 years

CNN13-06-2025
FacebookTweetLink
Follow
There's a video on Luka Krizanac's phone that captures him making coffee at home on an espresso machine. It's the type of video anyone might take to show off a new gadget to friends or recommend a favorite bag of beans. But the normalcy is exactly what makes it extraordinary for Krizanac – because just a few months ago, he didn't have hands.
Krizanac lost parts of his arms and legs at age 12 after a mismanaged infection led to sepsis and severe complications that required amputation. Last fall, nearly 17 years later, he received a double hand transplant at Penn Medicine.
Hand transplants are rare: Only 148 had been performed worldwide as of mid-2023, according to one study, and not all were double transplants.
More than 20 people were involved in Krizanac's surgery, which lasted about 12 hours and followed years of practice.
As the anesthesia was wearing off, Krizanac turned to one of the nurses at his bedside and said, 'Look how beautiful my hands are.'
He doesn't remember that moment – it was later recounted to him by the nurse – but the profound sentiment remains.
'I don't mean that just in an aesthetic way, but just a deep feeling of being whole again as a human,' he said.
For Krizanac, living without hands was more challenging than living without legs. Hands are required for thousands of essential everyday things, and the prosthetics he had simply couldn't fill the need as well as the prosthetics he had for his legs, he said.
'I don't think the question is even, 'What can't you do?' It's 'How can you live?' ' he said. 'With your legs, you walk. With your hands, you do thousands of things, from eating, taking care of yourself, to cooking, to expressing yourself. So trying to compensate for lack of arms with a plastic robotic hand is just impossible.'
The childhood he knew before ceased to exist, and he was confronted with a loss of independence, relying heavily on the strong support of loving family and friends.
'As you grow up, you want more independence. Naturally, as humans, we should be independent once we grow up,' Krizanac said. 'I was not able to achieve that due to lack of working hands. So that need increased, definitely, over time.'
Krizanac was adamant about not letting his disability define him and maintained a positive outlook by trying to live in the present, but he and his family continued to search for ways to help improve his quality of life.
They pursued hand transplantation for years, but numerous obstacles – including insurance coverage and a lack of access to skilled providers – stalled progress.
'I knew that the solution existed for my problem, and the question was how to reach that solution,' Krizanac said.
In 2018, about a decade after he lost his hands, a series of fortuitous connections brought Krizanac from his home in Switzerland to Dr. L. Scott Levin's office in Philadelphia.
Levin, chair emeritus of the Department of Orthopaedic Surgery and professor of plastic surgery at Penn Medicine, was immediately impressed by Krizanac's poise, and he quickly endeared himself to the full team.
'For a variety of reasons, he was a superb candidate for hand transplant,' Levin said. 'He fulfilled every characteristic: intelligent, informed, incredible family support.'
But another set of challenges – including a global pandemic and wounds that had developed on Krizanac's legs – delayed the process even further.
'During the pandemic, we had to put things on hold,' Levin said. 'And for the reason that he had open wounds and skin breakdown [on his legs], he would have never been allowed to have his hand transplant, because the open wounds and the risk of infection … would have prevented us from proceeding.'
But Levin and a colleague flew out to Switzerland to treat his legs, diving into preparations for the hand transplant once back in Philadelphia while Krizanac healed.
Preparing for a double hand transplant generally takes about two years, barring other complications. But by late 2024, Levin and his team were ready. They had completed more than dozen rehearsal sessions, mapping out the intricate steps needed to blend nerves, muscles, blood vessels and bones.
Krizanac moved to Philadelphia and did his best to enjoy his stay while anxiously awaiting an update.
The call came on a rainy Sunday afternoon about two months later: There was a match. The Gift of Life, an organ donation program, had found donor hands from a person who had the right skin tone, size and gender – a unique set of considerations hat can make the match process more complex than some others.
In a matter of minutes, Krizanac was packing up and heading over to the hospital, and he was in his room within an hour.
'When you decided something is right for you over the years and you are determined to work towards this goal, once you get the green light, there is no thinking,' Krizanac said. 'I did not have any reservations about the procedure. I was fully confident that after 17 years, I knew what was right for me.'
A well-orchestrated team – including plastic surgery, orthopedic surgery, transplant specialists, anesthesia and nursing – worked concurrently on Krizanac and the donor.
After blood vessels were sutured together, circulation was monitored with various devices. Nerves take time to regenerate, so it was impossible to know in the operating room whether that part of the operation had been successful.
'We count on the nerves to regenerate, but that's not assured. All we can do is technically do the best coaptation, the best nerve repair we can do day of injury with incredible precision using the operating microscope,' Levin said. 'With a little luck, if you will, and careful planning and execution of the operation, the nerves from the donor will grow into the muscles.'
Today, Krizanac is healing exceptionally well, Levin said. Nerves will continue to grow into his arms, and his recovery will continue to evolve over the next few years.
'The sensation, the ability to feel, improves. His strength gets more. He starts to get back the fine muscles in the hand,' Levin said. 'He's well on his way. Of all the transplant patients we've seen, his neural recovery has been the most accelerated.'
In addition to three or four physical therapy sessions each week, Krizanac is taking a few medications to help keep his body from rejecting the hands – a regimen similar to that of someone who had a kidney transplant. One of the medications, a calcineurin inhibitor called tacrolimus, has also been found to help with nerve regeneration.
Krizanac feels that he's on a path toward regaining independence, too. About a month after his surgery, he was using his phone with his new hands. And while washing his hands a few months later, he was surprised when the feeling of cold water made him jump back.
'I reflexively pulled back from the cold water. And this was really an a-ha moment where I thought, 'Oh, my God, I feel the temperature of the water,'' he said.
Hand transplantation is considered an elective 'quality of life' procedure, but Levin says there's an obligation for the medical field to provide the same level of care and consideration for patients like Krizanac as there would be for someone who needed a liver transplant – as long as they are properly prepared and informed.
'This is a field of transplantation that must continue to be supported. Our research, our clinical care, our education,' he said. 'For this field to be thwarted by the inability for insurance to pay for this or other agencies to accept it – for specific patients – that would be really a crime.'
Krizanac has ambitious goals for himself that are starting to feel more real, like hopefully getting a driver's license. Really, he just wants to be a regular adult guy.
'Even though everything is recovering, even though this process is highly complex in terms of surgery and rehabilitation, these are two healthy hands, and it's just a question of time and commitment until that is regained,' he said.
For now, smaller things bring him great joy. He recorded the video of himself making espresso because he's honing his skills as an amateur barista – a hobby that he wouldn't have been able to pursue without his hand transplant.
'I'm more of a cappuccino guy, but he can make me espresso anytime he wants,' Levin said.
CNN's Asuka Koda contributed to this report.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

US pediatric group breaks with CDC advice, recommends COVID vaccines for young children
US pediatric group breaks with CDC advice, recommends COVID vaccines for young children

Yahoo

time19 minutes ago

  • Yahoo

US pediatric group breaks with CDC advice, recommends COVID vaccines for young children

The American Academy of Pediatrics released its vaccine recommendations on Aug. 19 in a break from federal guidance shaped by Health and Human Services Secretary Robert F. Kennedy Jr. The AAP, in tandem with multiple other professional medical associations, previously decried a May announcement made by Kennedy Jr. that the COVID-19 vaccine would no longer be included in the Centers for Disease Control's recommended immunizations for healthy children and pregnant women, a move that went against previous expert guidance and bypassed the normal scientific review process. The AAP, a professional organization of over 65,000 board-certified pediatricians dedicated to advancing children's medicine, said in a June 26 statement that it would "continue to publish its own evidence-based recommendations and schedules," as the creation of federal immunization policy is 'no longer a credible process." Kennedy Jr. drew further ire from medical communities when he fired all 17 original members of the Advisory Committee on Immunization Practices, the committee of health experts that provides guidance on vaccine use to the CDC, replacing them with members that critics have called unqualified. Some of the members, like Kennedy Jr., have a history of anti-vaccine advocacy and involvement in anti-vaccine groups. Here's what to know about the new AAP guidance and how it differs from federal guidelines. What is the AAP guidance on COVID-19 vaccines for children? The AAP schedule lists which vaccines children should get at certain ages and provides updated guidance on influenza, RSV, and COVID-19 immunizations for children and adolescents from birth to age 18. The schedule recommends that all children between six months and 23 months receive the latest COVID-19 vaccine to reduce the chance of serious illness. Children and adolescents aged 2 to 18, without other high-risk factors like immunosuppression, can receive and should be offered the vaccine if they were not previously immunized, according to the guidance. Children, teens, and adults alike who are at increased risk of serious infection should receive the vaccine if they have not already, AAP said, adding that its recommendation differed from the CDC, which it said is now staffed with people who have a history of spreading vaccine misinformation. "The AAP will continue to provide recommendations for immunizations that are rooted in science and are in the best interest of the health of infants, children, and adolescents," AAP President Dr. Susan J. Kressly, MD, said in a statement. "Pediatricians know how important routine childhood immunizations are in keeping children, families and their communities healthy and thriving." What is the federal guidance on COVID-19 vaccines for children? The CDC did not go as far as completely removing COVID-19 vaccination from its immunization schedule despite Kennedy Jr.'s insistence. Instead, the agency changed its language from recommending the vaccine annually to suggesting parents consult with their child's physician on whether to vaccinate. Kennedy Jr. previously said that the CDC planned only to recommend the COVID vaccine for people over the age of 65 and those at high personal risk of infection, though the agency's website still contains information recommending it for everyone over the age of six months. A notice on the top webpages on the topic reads, "COVID-19 vaccine recommendations have recently been updated for some populations. This page will be updated to align with the updated immunization schedule," as of Aug. 19. This change to whom the vaccine is recommended could make it harder for others who want the COVID-19 vaccine to get it, experts warned. Since insurance coverage typically follows federal recommendations, anyone who wants the shot but isn't on the CDC's recommendation list may have to pay the price out of pocket HHS Communications Director Andrew Nixon defended the decision in a statement to USA TODAY, accusing the AAP, which receives funding from pharmaceutical companies like Pfizer, of failing to have proper conflict-of-interest safeguards in place. "By bypassing the CDC's advisory process and freelancing its own recommendations, while smearing those who demand accountability, the AAP is putting commercial interests ahead of public health and politics above America's children," Nixon said. Kennedy Jr. shared a separate response on social media on Aug. 19, pointing out that the agency's top donors are four companies that "make virtually every vaccine on the CDC recommended childhood vaccine schedule" and saying that the AAP recommendations are "corporate-friendly" and may "promote commercial ambitions of AAP's Big Pharma benefactors" instead of public health. "AAP should also be candid with doctors and hospitals that recommendations that diverge from the CDC's official list are not shielded from liability under the 1986 Vaccine Injury Act," his post concluded. USA TODAY reached out to AAP for comment on Aug. 19 but has not received a response. The new Advisory Committee on Immunization Practices didn't vote on COVID-19 vaccine recommendations when they met in June and are expected to reconvene in "September/October," according to the CDC. The FDA has signaled intentions to revoke the Pfizer COVID-19 shot for young, healthy children. In early August, HHS announced that it would pull $500M in funding from mRNA vaccine research and development. This article originally appeared on USA TODAY: Young kids should receive COVID vaccine despite CDC advice: AAP Solve the daily Crossword

XtalPi Signs MOU with Dong-A ST for Joint Research and Development of Immunology and Inflammation Therapies
XtalPi Signs MOU with Dong-A ST for Joint Research and Development of Immunology and Inflammation Therapies

Yahoo

timean hour ago

  • Yahoo

XtalPi Signs MOU with Dong-A ST for Joint Research and Development of Immunology and Inflammation Therapies

CAMBRIDGE, Mass., Aug. 19, 2025 /PRNewswire/ -- XtalPi announced on the 20th that it signed a Memorandum of Understanding (MOU) with Korea's leading pharmaceutical company Dong-A ST, to jointly develop therapeutics for immunological and inflammatory diseases. This collaboration will be based on XtalPi's intelligent and automated drug discovery platform, which integrates artificial intelligence (AI), quantum physics, and large-scale automated robotic experiments. The two companies plan to co-identify targets and discover first-in-class or best-in-class drug candidates using XtalPi's proprietary AI-driven drug discovery platform. The XtalPi platform combines the speed and generative power of AI with the accuracy of its robotic lab-in-the-loop to accelerate drug discovery and vastly expand the explorable chemical space. This integrated workflow spans deep-learning-based molecule design, quantum physics and molecular dynamics simulations for predicting drug-target interactions, automated chemical synthesis, and experimental validation of candidate compounds' key pharmaceutical properties. Leveraging its expertise in immunology and inflammation as well as its experience in small molecule drug development, Dong-A ST will actively participate throughout the entire R&D process—including candidate validation, efficacy and safety testing, and the formulation of preclinical and clinical development strategies. The company also plans to explore strategies for pipeline expansion and assess commercialization potential. Through this partnership, Dong-A ST aims to strengthen its pipeline in the immunology and inflammation space and expand its R&D scope beyond small molecule therapeutics into areas such as targeted protein degradation (TPD), biologics, antibody-drug conjugates (ADC), and gene therapies. John Wang, Senior Vice President of Drug Discovery at XtalPi, stated: "The combination of Dong-A ST's extensive expertise and XtalPi's proven AI-robotics platform is well-positioned to translate scientific innovation into competitive precision medicines. Together, we aim to rapidly discover and rigorously validate novel drug candidates across multiple modalities to unlock unique market opportunities, and deliver transformative therapies for global patients." Jae-Hong Park, Head of R&D at Dong-A ST, remarked, "This collaboration marks a pivotal step in expanding Dong-A ST's R&D capabilities," adding, "By leveraging synergies with XtalPi's AI platform, we expect to accelerate the development of next-generation treatments for immune and inflammatory diseases." Meanwhile, both Dong-A ST and XtalPi operate open innovation offices in Boston, USA. This geographic proximity will facilitate closer and more efficient collaboration throughout the drug discovery process. About Dong-A ST Dong-A ST Co., Ltd. ( was established in 1932 and is a leading Korean pharmaceutical company engaged in the development, manufacturing, and commercialization of ethical drugs, biosimilars, medical devices, and diagnostics. Its key products include Stillen (gastritis), Zydena (erectile dysfunction), Motilitone (functional dyspepsia), and Imuldosa (ustekinuma biosimilar). Leveraging strong R&D capabilities and a history of innovation, Dong-A ST is expanding its pipeline in immunology, inflammation, neurological disease, metabolic diseases, and oncology, while advancing into new modalities such as biologics, ADCs, TPD, and gene therapies. About XtalPi XtalPi Holdings Limited (XtalPi, was founded in 2015 by three physicists from the Massachusetts Institute of Technology (MIT). It is an innovative R&D platform powered by quantum physics, artificial intelligence, and robotics. By integrating first-principles calculations, AI algorithms, high-performance cloud computing, and standardized automation systems, XtalPi provides digital and intelligent R&D solutions for companies in the pharmaceutical, materials science, agricultural technology, energy, new chemicals, and cosmetics industries. View original content to download multimedia: SOURCE XtalPi Inc. Sign in to access your portfolio

FDA warns against eating certain shrimp sold at Walmart amid investigation into radioactive contamination
FDA warns against eating certain shrimp sold at Walmart amid investigation into radioactive contamination

CNN

timean hour ago

  • CNN

FDA warns against eating certain shrimp sold at Walmart amid investigation into radioactive contamination

Federal agencies Food & healthFacebookTweetLink Follow The US Food and Drug Administration on Tuesday urged the public not to eat certain bags of frozen raw shrimp sold at Walmart, citing concerns about unsanitary conditions and radioactive contamination found in shipments from the same supplier. The FDA said that a radioactive isotope, cesium-137, was detected in a sample of breaded shrimp detained at US ports – in Los Angeles, Houston, Savannah, and Miami – from an Indonesian supplier named BMS Foods. Those contaminated shipments never reached the US market. However, because Walmart's raw frozen shrimp came from the same supplier – and the agency said it 'appears to have been prepared, packed, or held under insanitary conditions whereby it may have become contaminated with Cs-137' – officials advised consumers to avoid eating them. The levels of cesium detected – about 68 becquerels per kilogram – were well below the FDA's intervention level of 1,200 Bq/kg. Still, regulators issued the advisory out of caution, citing the potential risks of cancer from long-term, low-dose exposure and problems at the supplier's facility. The advisory applies to 2-pound Great Value bags of white vannamei shrimp, all carrying a best-by date of March 15, 2027. They were distributed to Walmart stores in at least 13 states: Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Missouri, Mississippi, Ohio, Oklahoma, Pennsylvania, Texas and West Virginia. The agency is advising consumers who purchased the shrimp to throw it away or return it, and, said an investigation is ongoing in conjunction with Indonesian seafood regulatory authorities. Walmart confirmed to CNN that it 'immediately recalled the product from impacted stores.' CNN has also reached out to the supplier for comment.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store